Predictors of mortality and disability in stroke-associated pneumonia by Tinker, Rory J et al.
Vol.:(0123456789) 
Acta Neurologica Belgica 
https://doi.org/10.1007/s13760-019-01148-w
ORIGINAL ARTICLE
Predictors of mortality and disability in stroke‑associated pneumonia
Rory J. Tinker1  · Craig J. Smith1,2 · Calvin Heal3 · Joao H. Bettencourt‑Silva4,6 · Anthony K. Metcalf5,6,7 · 
John F. Potter5,6,7 · Phyo K. Myint4,5,6
Received: 6 January 2019 / Accepted: 23 April 2019 
© The Author(s) 2019
Abstract
Whilst stroke-associated pneumonia (SAP) is common and associated with poor outcomes, less is known about the determi-
nants of these adverse clinical outcomes in SAP. To identify the factors that influence mortality and morbidity in SAP. Data 
for patients with SAP (n = 854) were extracted from a regional Hospital Stroke Register in Norfolk, UK (2003–2015). SAP 
was defined as pneumonia occurring within 7 days of admission by the treating clinicians. Mutlivariable regression models 
were constructed to assess factors influencing survival and the level of disability at discharge using modified Rankin Scale 
[mRS]. Mean (SD) age was 83.0 (8.7) years and ischaemic stroke occurred in 727 (85.0%). Mortality was 19.0% at 30 days 
and 44.0% at 6 months. Stroke severity assessment using National Institutes of Health Stroke Scale was not recorded in the 
data set although Oxfordshire Community Stroke Project was Classification. In the multivariable analyses, 30-day mortal-
ity was independently associated with age (OR 1.04, 95% CI 1.01–1.07, p = 0.01), haemorrhagic stroke (2.27, 1.07–4.78, 
p = 0.03) and pre-stroke disability (mRS 4–5 v 0–1: 6.45, 3.12–13.35, p < 0.001). 6-month mortality was independently 
associated with age (< 0.001), pre-stroke disability (p < 0.001) and certain comorbidities, including the following: dementia 
(6.53, 4.73–9.03, p < 0.001), lung cancer (2.07, 1.14–3.77, p = 0.017) and previous transient ischemic attack (1.94, 1.12–3.36, 
p = 0.019). Disability defined by mRS at discharge was independently associated with age (1.10, 1.05–1.16, p < 0.001) and 
plasma C-reactive protein (1.02, 1.01–1.03, p = 0.012). We have identified non-modifiable determinants of poor prognosis 
in patients with SAP. Further studies are required to identify modifiable factors which may guide areas for intervention to 
improve the prognosis in SAP in these patients.
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Introduction
Stroke places a large burden on society causing approxi-
mately 11.8% of global deaths making it the second most 
common cause of death after ischaemic heart disease [1]. 
It is also the third most common cause of disability repre-
senting 4.5% of global Disability-Adjusted Life Years [2]. Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1376 0-019-01148 -w) contains 
supplementary material, which is available to authorized users.
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Pneumonia is a frequent clinical complication after stroke, 
occurring most often within the first week (stroke-associ-
ated pneumonia, SAP) [3–5]. It has been estimated that SAP 
complicates around 14% of strokes, although the frequency 
varies considerably between studies [5]. When SAP occurs, 
it has major clinical implications and has the highest attrib-
utable rise in mortality of all medical complications follow-
ing stroke (estimated to be between 10.1 and 37.3%) [5]. 
Additionally, SAP has a large economic burden on medical 
systems with the cost of each case estimated to be £14,371 
in the UK [6].
Currently the factors that determine mortality and mor-
bidity in SAP are unknown [7]. This is in contrast to com-
munity-acquired pneumonia (CAP) where prognostic factors 
have been investigated leading to the development of prog-
nostic scores (CURB-65) [8] which guide clinicians with 
regard to choice of antibiotics and route of administration. 
This has led to the care of pneumonia becoming more cost 
efficient, efficacious and personalised [9]. The use of CURB-
65 has demonstrated that successful implementation of a 
risk stratification score in CAP can improve outcome, and a 
similar prognostic score in SAP could be of use in clinical 
practice and research [9]. The purpose of this study was, 
therefore, to investigate the factors that influence mortality 
and disability in SAP prior to development of a future prog-
nostic score. The specific aim of the current study was to 
determine which patient-related factors were associated with 
mortality (at 1 and 6 months) and unfavourable functional 
outcomes in patients with SAP.
Methods
We retrospectively analysed a prospectively collected, 
hospital-based stroke registry which included all consecu-
tive stroke admissions to a regional stroke register. Ethical 
approval for the establishment of the database was granted 
by the Newcastle and Tyneside National Health Service 
(NHS) Research Ethics Committee (12/NE/0170).
Data source
We selected eligible patients with confirmed stroke and SAP 
from the Norfolk and Norwich University Hospital (NNUH) 
Stroke Register. The register collects clinical information 
from consecutively admitted stroke patients to the tertiary 
centre in Norfolk, UK, which provides acute stroke ser-
vices to a catchment population of 750,000 people. The 
cohort for the present study was constructed by extraction 
of anonymised electronic data of consecutive stroke admis-
sions over 12 years (from January 2003 to April 2015) onto 
a secure central database. The data collection methods have 
been previously reported [10, 11]. In brief, acute stroke 
cases were diagnosed by the same firm of stroke physicians 
based on clinical features and imaging (CT/MRI). SAP was 
defined as pneumonia diagnosed within 7 days of admission. 
The diagnosis of pneumonia was made by clinicians as per 
British Thoracic Society (BTS) guidelines which require 
confirmation changes on chest radiography consistent with 
pneumonia [12].
Data collection
The incidence of SAP and other prevalent comorbidities 
were retrieved from specific hospital electronic and/or 
paper patient records and coded in the 10th revision of 
the International Classification of Disease (ICD-10). The 
following patient baseline variables were available: age; 
sex; date of admission; date of discharge; discharge des-
tination; Oxfordshire Community Stroke Project (OCSP) 
classification; type of stroke (haemorrhagic or ischaemic 
stroke); length of hospital stay (LOS); pre-stroke modi-
fied Rankin Scale (mRs) (6-point score 0–5); post stroke 
discharge mRS (7-point score 0–6 incorporating death as 
score 6) and antiplatelet treatment (at admission). The 
dataset also included routine blood tests. Blood tests 
results were included in the analysis if they were taken 
within ± 5 days of the diagnosis of SAP. The specific hae-
matological and biochemical variables available for inves-
tigation were as follows: urea and electrolytes (Us and Es); 
full blood counts (FBC); International Normalized Ratio 
(INR), thyroid function tests (TFTs) and acute inflamma-
tory response markers (total white cell count (WCC) and 
C reactive protein (CRP). Comorbidities included previ-
ous: stroke; transient ischaemic attack (TIA); coronary 
heart disease (CHD); myocardial infarction (MI); atrial 
fibrillation; congestive heart failure (CHF), hypertension; 
dyslipidaemia; diabetes mellitus; peripheral vascular 
disease (PVD); chronic obstructive pulmonary disease 
(COPD); asthma; previous pneumonia; chronic kidney 
disease (CKD); malignancy; vascular dementia; and Alz-
heimer’s disease. The length of survival after stroke was 
derived from time between the patient’s admission to hos-
pital and the date of their death (if applicable) or censor 
date (30 or 90 days post admission). Electronic linkage 
with the Office of National Statistics (ONS) for mortality 
data enables complete follow up for mortality.
Statistical analysis
SPSS for Windows version 23.0 (SPSS Inc., Chicago, IL, 
USA) was used to perform the statistical analysis. The 
primary outcomes of interest were mortality at 1 month 
and at 6 months from admission to hospital for the index 
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stroke. The secondary outcomes were poor functional 
outcome defined as mRs score at discharge (0–4 = good, 
5 + = bad), dichotomised based on the median discharge 
mRS.
Univariable logistic binary regression models were used 
to investigate the associations between discrete categori-
cal variables and mortality. Univariable linear regression 
models were constructed to examine the associations 
between continuous variables and mortality. Following 
this, variables were inputted into multivariable logistic 
regression models based on p value threshold of < 0.10 
(10% significance level) in the univariable analyses, clini-
cal experience, and the literature on stroke and pneumonia 
prognostic factors. The dataset for mortality was analysed 
twice. The first analysis was restricted to variables with 
complete data sets with no missing variables (all baseline 
characteristics, including comorbidities) (analysis 1). As 
there were missing values for blood tests and pre stroke 
mRS, in the second round of analysis all variables were 
analysed regardless of completeness of data set. This leads 
to the introduction of the blood results and pre stroke mod-
ified rankin scores into the analysis (analysis 2).
To further investigate the effect of age and pre stroke dis-
ability, the cohort was stratified into nine distinct groups 
based on increasing age and pre stroke disability. All vari-
ables were analysed regardless of data completeness. These 
strata were then analysed in multivariable logistic regres-
sion models (correcting for factors influencing disability in 
the previous multivariable models) at both 1 and 6 months. 
This resulted in correction for age and the following com-
modities: dementia, lung cancer and TIA at 6 months. At 
1 month this resulted in correction for age, the type of stroke 
(haemorrhagic) and pre stroke disability.
Results
854 patients with SAP were included in the final analysis 
from the cohort of 11,886 in the NNUH register. The base-
line characteristics are summarised in Table 1. Overall, the 
median (IQR) age was 83 year (77.5–88.5), 49% were male 
and the majority of patients presented with ischaemic stroke 
(85.1%).
In the univariable regression models, 30-day mortality 
(Table 1 of Supplement) was associated with the following: 
increasing age (for each additional life year), stroke subtype 
(haemorrhagic) and the following comorbidities: dementia, 
lung cancer. In the univariate regression models mortality 
at 6 months (Table 2 of Supplement) was associated with 
increasing age (for each additional life year), stroke subtype 
(haemorrhagic) and the following comorbidities: dementia, 
lung cancer.
In the univariable analyses, disability at discharge was 
predicted by increasing age and serum C-reactive protein 
levels (Table 3 of Supplement).
When analysis was conducted with only complete data 
sets with no missing variables (analysis 1, Table 2) mortal-
ity at 30 days was predicted by the following: a patient’s 
increasing age (for each additional life year), the type of 
stroke (haemorrhagic) and the following commodities: 
dementia, lung cancer.
When all available data were analysed (regardless if the 
data set had missing variables or not) (analysis 2 Table 2), 
multivariable regression models predicted mortality at 
30 days based on the following variables increasing age 
(for each additional year of life year), stroke subtype 
(haemorrhagic) and pre stroke modified rankin.
Multivariable regression models which included only 
the complete data sets with no missing values (analysis 1, 
Table 2) predicted mortality at 6 months bythe following: 
a patient’s increasing age (for each additional life year) 
and the following comorbidities: dementia, lung cancer 
and TIA.
When all available data were analysed (regardless if the 
data set had missing variables or not) (analysis 2 Table 2) 
mortality was predicted at 6 months by: a patients’ increas-
ing age (per a year), pre stroke disability, and a previous 
episode of pneumonia. The inclusion of pre stroke modified 
Table 1  Baseline characteristics of participating patients
Cohort with SAP
n 854
Male (%) 419 (49.1)
Age group, n (%)




 90 + 158 (19.4)
Median age (IQR) (years) 83 (77.5–88.5)
Age standard deviation (years) 8.749




 Hypertension, n (%) 324 (37.9)
 Atrial fibrillation 241 (28.2)
 Diabetes, n (%) 102 (11.9)
Mortality
 7-day mortality, n (%) 36 (4.2)
 30-day mortality, n (%) 164 (19.2)
 6-month mortality, n (%) 378 (44.2)
 Final mortality, n (%) 523 (61.2)
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Rankin, therefore, removed comorbidities (dementia and 
lung cancer). All multivariable models for mortality are 
displayed in Table 1.
In the multivariable logistic regression model, disability 
at discharge was predicted by increasing age (per year) and 
serum C-reactive protein levels (Table 2).
When the cohort was split into 9 strata for age and pre-
stroke disability, mortality at both 1 and 6 month was associ-
ated with being in an older age group and being in a more 
disabled Rankin group (Fig. 1; Table 4 of Supplement). Age 
and disability were of greater predictive value at 30 days.
Discussion
SAP has a major impact on morbidity and mortality fol-
lowing stroke [10]. As the prognostic factors are currently 
unknown, we aimed to explore clinical characteristics pre-
dictive of poor outcome in SAP. The major findings of the 
study are that mortality is associated with non-modifiable 
patient characteristics including increasing age, haemor-
rhagic stroke sub-type, pre-stroke disability and comorbidi-
ties. An additional finding of the study was that disability 
after the stroke was predicted by age and serum CRP.
The characteristics of the patients who developed SAP is 
similar to previously reported literature. The patients tended 
to be older, frailer and had higher number of comorbidities 
[9, 11]. This is in keeping with previous analysis of the full 
cohort from which the SAP sample was extracted that has 
shown those patients who develop SAP after stroke older, 
more frail and more comorbid then the patients who do not 
[9].
When the results of this study are compared to the litera-
ture for CAP which is usually caused by viral or bacterial 
infection there appear to be some overlap. Age predicts sur-
vival at 1 month and 6 months in CAP in the literature and 
for SAP the current study [8, 13–15]. When comparing to 
the CURB-65 score for CAP, we did not find an association 
between serum urea concentrations at diagnosis of SAP and 
mortality [9]. It is difficult to conclude if this is a true finding 
or due to the incomplete data for urea concentration (sees 
limitations of study) and therefore the current study cannot 
exclude such an association and this should be investigated 
in the future studies of SAP.
Prestroke mRS has been shown to be a risk factor for the 
development of pneumonia after stroke, but the finding that 
it is associated with death after SAP has not been reported 
to our knowledge [7]. The results of this study are in keep-
ing with the general literature on stroke prognosis [16–18]. 
The current study also suggests that age and disability are 
of greater prediction for mortality in the first month after the 
stroke than at 6 months suggesting they are both of greater 
utility acutely than long term.
Table 2  Factors associated with mortality and discharge disability in the multifactorial analysis
30-day mortality 6-month mortality Discharge disability
Complete only All Complete only All –
Independent variable n OR (95% CI), p OR (95% CI), p OR (95% CI), p OR (95% CI), p OR (95% CI), p
Age (per 1-year 
increase)
854 1.04 (1.01, 1.06), 
0.005
1.04 (1.01, 1.07), 
0.011
1.07 (1.05, 1.09, 
< 0.001)




Haemorrhagic stroke 854 2.49 (1.26, 4.92), 
0.009
2.49 (1.26, 4.92), 
0.032
–
Comorbidities – – – – – –
All dementia 854 12.90 (7.50–22.20), 
< 0.001
– 6.53 (4.73,9.03), 
< 0.001
–
Lung cancer 854 8.91 (2.70–29.38), 
0.001
– 2.07 (1.14, 3.77), 
0.017
–
TIA 854 – – 1.94 (1.12, 3.36) – –
Previous pneumonia 854 – – – 1.77 (1.10, 2.85), 
0.020
–
Pre-stroke disability – – – – – –
0–1 220 – 1 – 1 –
2–3 101 – 4.65 (2.36, 9.15), 
< 0.001
– 2.06 (1.21, 3.51), 
0.008
4–5 94 – 6.45 (3.12, 13.35), 
< 0.001




– – – – 1.02 (1.01–1.03), 
0.012
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To the best of our knowledge, the finding that age and 
peripheral inflammatory state affect disability after SAP 
has not been reported previously [19]. In addition our find-
ings are in keeping with the general literature with regard 
to disability after stroke [18, 19]. The literature sug-
gests that older patients are more likely to have a higher 
level of disability post stroke (like SAP) [20]. Additional 
inflammatory markers (including CRP) have been associ-
ated with poor outcome after stroke and greater disabil-
ity [18]. Also, plasma CRP detects early development of 
stroke-associated infections and may have a role in diag-
nostic criteria for SAP [14]. It is therefore likely that the 
association with CRP could be due to more severe cases of 
SAP and higher stroke severity (which are more likely to 
cause disability) leading to higher levels of inflammatory 
makers [21]. This could therefore mean that CRP repre-
sents both a diagnostic marker for SAP and also the sever-
ity and prognosis of SAP. Identification of increase CRP 
as a poor prognostic marker in SAP provides an intriguing 
possibility that the attempt to reduce inflammation and 
Fig. 1  Forest plot showing 
effect of stratification of age and 
pre-stroke mRS on, a mortal-
ity at 30 days and b mortality 
at 6 months. Each data point 
represents OR with 95% CI
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possible associated infection may reduce the excess mor-
tality and morbidity burden of SAP.
The current study has some limitations. Firstly, it is based 
on secondary analyses of a single prospective cohort from 
a geographically defined part of the UK. We have various 
missing values limiting the multiple regression models that 
were subsequently created. However, this should not have 
impact on internal association between predictors and out-
comes. Furthermore, the study was based on the retrospec-
tive analysis of digitalised patient records. This meant that 
the timings of blood results inputted into the study did not 
always correspond exactly to the diagnosis of SAP further 
limiting the regression model. The data also lacked basic 
physiological and functional data measurements (oxygena-
tion, blood pressure, respiratory rate, dysphgia status) and 
cognition (e.g. MMSE) as well as information on stroke 
severity (e.g. NIHSS scores) [22]. Many of these variables 
have been associated with survival post stroke or CAP and 
therefore have the potential to be associated with survival 
post SAP and potential confounders to the relationship 
between outcome and the variables we found to be associ-
ated [23, 24]. For example, NIHSS is independently associ-
ated with both morbidity and mortality post-stroke as well 
the risk of developing SAP. However, we were able to con-
trol for Oxfordshire Community Stroke Project classification 
as indicator of stroke severity. Additionally in some cases, 
clinical decision may be made to withdraw treatment at the 
time of SAP diagnosis and this may have impact. As a large 
real world observational study, we are not able to address 
in this work.
The strengths of the study include employing a consist-
ent and reproducible data collection at a single centre from 
the same groups of clinicians and their team making data 
collection accurate, reproducible. Secondly the study sam-
ple size was large and comprehensive covering many of the 
large number comorbidities which has been shown to have 
prognostic value in stroke.
This study describes factors influencing mortality and 
disability after SAP which are both largely consistent with 
the literature for both pneumonia and stroke. To expand on 
these findings it would be helpful to conduct a prospective 
study on the prognostic factors for SAP on different cohorts. 
Blood tests and physiological observations could then be 
taken at the specific time of diagnosis with SAP.
Finally in order to make this data clinically applicable 
further research is required to develop the findings into a 
prognostic score. Such a score could be used at the bedside 
to identify stroke patients at greatest risk of SAP creating 
the possibility to personalise their treatment and ultimately 
reduce mortality.
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